Last reviewed · How we verify
Cerium Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SNP-ACTH (1-39) Gel | SNP-ACTH (1-39) Gel | phase 3 | corticosteroid | melanocortin receptors | Endocrinology |
Therapeutic area mix
- Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 1 shared drug class
- Balmoral Medical company · 1 shared drug class
- Bausch & Lomb Incorporated · 1 shared drug class
- Dr. Reddys Laboratories, SA · 1 shared drug class
- Edesa Biotech Inc. · 1 shared drug class
- Evon Medics LLC · 1 shared drug class
- Federal University of São Paulo · 1 shared drug class
- Kala Pharmaceuticals, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cerium Pharmaceuticals, Inc.:
- Cerium Pharmaceuticals, Inc. pipeline updates — RSS
- Cerium Pharmaceuticals, Inc. pipeline updates — Atom
- Cerium Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cerium Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cerium-pharmaceuticals-inc. Accessed 2026-05-16.